Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.

Authors
Type
Published Article
Journal
Clinical Pharmacology & Therapeutics
1532-6535
Publisher
Wiley Blackwell (Blackwell Publishing)
Publication Date
Volume
97
Issue
2
Pages
128–130
Identifiers
DOI: 10.1002/cpt.29
PMID: 25670516
Source
Medline
License
Unknown

Abstract

Neuropathic pain is a large unmet medical need. The angiotensin II type 2 (AT2 ) receptor is a target with promising data in rodent models of peripheral neuropathic pain. The AT2 receptor has attracted attention on the basis of human data from a proof-of-concept clinical trial showing that oral EMA401, a highly selective, peripherally restricted, small molecule AT2 receptor antagonist, at 100 mg twice-daily for 4 weeks, alleviated postherpetic neuralgia, an often intractable type of peripheral neuropathic pain.

Statistics

Seen <100 times